Impact of pharmaceutical care for improving health-releated quality of life in patients with gastrointestinal pathology

The gastrointestinal pathology is one of the most common health problems, with direct implications in reducing the patient's quality of life. The COVID-19 disease, which has become a global public health emergency since early 2020, affects both the respiratory and digestive systems. The profile of the gastrointestinal disorders, thus becomes much more complex, being able to indicate an early infection with the SARS-CoV-2 virus. In this context, the open-circuit pharmacy beyond the important role of treating patients, has active implications in the education and prevent program of spreading the SARS-CoV-2 virus, at least until the until the efficacy of the COVID-19 vaccine is demonstrated.